bispecific antibodies vs car-t cells in dlbcl: the benefit of car-t therapy
Published 9 months ago • 670 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
2:52
current immunotherapeutic approaches in dlbcl: the value of car-t cells and bispecific antibodies
-
2:38
weighing up the pros and cons of car-t therapy and bispecific antibodies in r/r dlbcl
-
2:52
comparing the efficacy and curative potential of car-t therapy & bispecific antibodies in r/r dlbcl
-
6:23
the benefits of bispecific antibodies over car-t cell therapy in lymphoma
-
1:14
the car t-cell strategy vs bispecific antibodies
-
19:39
t-cell engagers: targets, challenges and opportunity
-
20:56
targets of car-t cell therapy
-
2:46
pros and cons of autologous and allogeneic car-ts
-
1:23
advantages of bispecific antibodies over car-t therapy in lbcl
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells
-
12:15
car-t vs bispecific antibodies for lymphoma
-
4:01
what are the differences between car t-cell therapy and bispecific antibodies?
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
4:27
the possibility of combining car-t therapy and bispecific antibodies in the treatment of nhl
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
2:34
car-t & bispecific antibodies in second-line dlbcl
-
2:37
efficacy of bispecific cd19/cd22 car t-cells in b-cell malignancies
-
2:27
the potential of car t-cell therapy in combination with antibodies for the treatment of all
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
1:13
the future of car t-cells and bispecific antibodies to treat myeloma
-
1:25
moving car t-cell therapy and bispecific antibodies in the consolidation setting
-
3:43
safety and efficacy of ytb323, a car t-cell therapy, in r/r dlbcl